Kalgene to use Affomix antibodies
This article was originally published in Scrip
Executive Summary
Affomix is to use its Y2HExpress automated high-throughput monoclonal antibody selection technology to generate antibodies against specific targets defined by the Canadian company Kalgene Pharmaceuticals.